Skip to main content

Table 2 Effect on PSA

From: A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer

Patient ID

Baseline

Day 29 (± 2)

Day 57 (± 2)

002–005

1353.10

1826.57

3150.50

002–007

89.00

91.22

108.53

002–008

108.50

190.23

265.74

002–009

1181.00

1141.30

1266.00

003-001

26.90

32.00

36.30

003-002

89.50

138.60

175.50

003-003

27.70

32.30

32.80

003–004

31.80

54.90

63.70

003–010

9.00

9.40

13.30

003–011

1424.00

1359.00

1268.00